Predictive and prognostic potential of TP53 in patients with advanced non-small cell cancer treated with EGFR-TKI: Analysis of a phase III randomized clinical trial (CTONG 0901)

Alexandros G.Sfakianakis shared this article with you from Inoreader Predictive and prognostic potential of TP53 in patients with advanced non-small cell cancer treated with EGFR-TKI: Analysis of a phase III randomized clinical trial (CTONG 0901) Μέσω Clinical Lung Cancer We investigated the potential use of mutant TP53 in prediction and prognosis of patients with non-small cell lung cancer. We analyzed data obtained from a phase III randomized clinical trial (CTONG 0901). Specific mutations in TP53 (exon 4 or 7) were independently correlated with survival in patients with EGFR mutations. This may help clinicians define precise target populations for treatment. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.